根据血压分析Omecamtiv Mecarbil在射血分数降低心衰中的效果:GALACTIC-HF试验
GALACTIC-HF试验事后分析评估Omecamtiv Mecarbil在基线收缩压≤100 mmHg的射血分数降低心衰患者中的疗效与耐受性。共分析8232例患者,其中1473例(17.9%)基线收缩压≤100 mmHg。该死因或心衰事件复合终点在低收缩压组中发生715例(48.5%),在高收缩压组中发生2415例(35.7%),Omecamtiv Mecarbil对低收缩压组的主要复合终点显示出更明显的减少趋势(HR 0.81;95%CI 0.70-0.94),且不改变收缩压,不增加不良事件风险。
要点
- 低收缩压(≤100 mmHg)心衰患者不良结局风险更高。
- Omecamtiv Mecarbil可能更有效降低低收缩压患者的主要复合终点。
- Omecamtiv Mecarbil不改变收缩压且耐受性良好。
核心结论
- 在GALACTIC-HF中,与安慰剂相比,Omecamtiv Mecarbil对低收缩压患者的复合终点减少幅度大且显著。
- Omecamtiv Mecarbil不改变收缩压,且无论收缩压水平如何均耐受良好。
研究设计与样本
- GALACTIC-HF试验的事后分析,纳入基线收缩压≥85 mmHg的射血分数降低心衰患者。
- 按基线收缩压分为≤100 mmHg组和>100 mmHg组,共分析8232例患者。
主要发现
- 基线收缩压≤100 mmHg组1473例(17.9%),>100 mmHg组6759例(82.1%)。
- 主要终点在收缩压≤100 mmHg组发生715例(48.5%),>100 mmHg组发生2415例(35.7%)。
- Omecamtiv Mecarbil对比安慰剂在收缩压≤100 mmHg组的主要复合终点HR为0.81(95%CI 0.70-0.94),>100 mmHg组HR为0.95(95%CI 0.88-1.03),交互作用P=0.051。
- 两组中Omecamtiv Mecarbil均不随时间改变收缩压值,且与安慰剂相比不增加不良事件风险。
关键数值与推荐
- 基线收缩压≤100 mmHg定义为低收缩压组,>100 mmHg为高收缩压组。
- 主要终点为至心血管死亡或首次心衰事件的时间。
临床怎么用
- 对于射血分数降低心衰合并低收缩压(≤100 mmHg)的患者,Omecamtiv Mecarbil可能提供更显著的复合终点获益,且不进一步降低血压。
- 使用Omecamtiv Mecarbil时无需担心收缩压进一步下降,耐受性良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Patients with heart failure with reduced ejection fraction and low systolic blood pressure (SBP) have high mortality, hospitalizations, and poorly tolerate evidence-based medical treatment. Omecamtiv mecarbil may be particularly helpful in such patients. This study examined its efficacy and tolerability in patients with SBP ≤100 mmHg enrolled in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF). METHODS AND RESULTS: The GALACTIC-HF enrolled patients with baseline SBP ≥85 mmHg with a primary outcome of time to cardiovascular death or first heart failure event. In this analysis, patients were divided according to their baseline SBP (≤100 vs. >100 mmHg). Among the 8232 analysed patients, 1473 (17.9%) had baseline SBP ≤100 mmHg and 6759 (82.1%) had SBP >100 mmHg. The primary outcome occurred in 715 (48.5%) and 2415 (35.7%) patients with SBP ≤100 and >100 mmHg, respectively. Patients with lower SBP were at higher risk of adverse outcomes. Omecamtiv mecarbil, compared with placebo, appeared to be more effective in reducing the primary composite endpoint in patients with SBP ≤100 mmHg [hazard ratio (HR), 0.81; 95% confidence interval (CI), 0.70-0.94] compared with those with SBP >100 mmHg (HR, 0.95; 95% CI, 0.88-1.03; P-value for interaction = 0.051). In both groups, omecamtiv mecarbil did not change SBP values over time and did not increase the risk of adverse events, when compared with placebo. CONCLUSION: In GALACTIC-HF, risk reduction of heart failure outcomes with omecamtiv mecarbil compared with placebo was large and significant in patients with low SBP. Omecamtiv mecarbil did not affect SBP and was well tolerated independent of SBP values.
引用
- Metra, Pagnesi, Claggett, et al. Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. Eur Heart J. 2022. PMID: 35675469. doi:10.1093/eurheartj/ehac293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。